NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
NextCure (NXTC) and LigaChemBio announced they will present a trial in progress poster for LNCB74, their B7-H4 targeted antibody-drug conjugate (ADC), at the upcoming ASCO Annual Meeting in Chicago. The Phase 1 study is evaluating LNCB74 as a monotherapy for advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer.
The first-in-human study includes dose escalation, safety, and biomarker backfills, followed by randomized dose expansion/optimization phases. The trial is currently in the dose escalation phase. According to NextCure's CMO, B7-H4 is an attractive target due to its high expression in multiple tumor types and limited expression in normal tissues. LNCB74 has shown promising preclinical results with a superior safety profile and potent anti-tumor activity.
NextCure (NXTC) e LigaChemBio hanno annunciato che presenteranno un poster sul trial in corso per LNCB74, il loro coniugato anticorpo-farmaco (ADC) mirato a B7-H4, al prossimo ASCO Annual Meeting di Chicago. Lo studio di Fase 1 valuta LNCB74 come monoterapia per tumori solidi avanzati, inclusi carcinoma ovarico resistente al platino, carcinoma mammario refrattario al trattamento, carcinoma endometriale, tumore delle vie biliari e carcinoma polmonare non a piccole cellule squamoso.
Lo studio di prima somministrazione nell'uomo comprende l'escalation della dose, la valutazione della sicurezza e l'analisi dei biomarcatori, seguiti da fasi di espansione e ottimizzazione della dose randomizzate. Attualmente il trial è nella fase di escalation della dose. Secondo il CMO di NextCure, B7-H4 è un target interessante grazie alla sua elevata espressione in diversi tipi tumorali e alla limitata espressione nei tessuti normali. LNCB74 ha mostrato risultati preclinici promettenti con un profilo di sicurezza superiore e un'attività antitumorale potente.
NextCure (NXTC) y LigaChemBio anunciaron que presentarán un póster sobre el ensayo en curso de LNCB74, su conjugado anticuerpo-fármaco (ADC) dirigido a B7-H4, en la próxima Reunión Anual de ASCO en Chicago. El estudio de Fase 1 evalúa LNCB74 como monoterapia para tumores sólidos avanzados, incluyendo cáncer de ovario resistente al platino, cáncer de mama refractario al tratamiento, cáncer de endometrio, cáncer de las vías biliares y cáncer de pulmón no microcítico escamoso.
El estudio de primera administración en humanos incluye la escalada de dosis, seguridad y análisis de biomarcadores, seguido de fases de expansión y optimización de dosis aleatorizadas. Actualmente, el ensayo se encuentra en la fase de escalada de dosis. Según el CMO de NextCure, B7-H4 es un objetivo atractivo debido a su alta expresión en múltiples tipos tumorales y expresión limitada en tejidos normales. LNCB74 ha mostrado resultados preclínicos prometedores con un perfil de seguridad superior y una potente actividad antitumoral.
NextCure (NXTC)와 LigaChemBio는 시카고에서 열리는 ASCO 연례회의에서 B7-H4를 표적으로 하는 항체-약물 접합체(ADC)인 LNCB74의 진행 중인 임상 시험 포스터를 발표할 예정이라고 밝혔습니다. 1상 연구는 백금 내성 난소암, 치료 저항성 유방암, 자궁내막암, 담도암, 편평 비소세포 폐암을 포함한 진행성 고형암에 대한 단독요법으로 LNCB74를 평가하고 있습니다.
인체 최초 투여 연구는 용량 상향 조정, 안전성 및 바이오마커 분석을 포함하며, 이후 무작위 용량 확장/최적화 단계가 진행됩니다. 현재 임상 시험은 용량 상향 조정 단계에 있습니다. NextCure의 최고의료책임자(CMO)에 따르면, B7-H4는 여러 종양 유형에서 높은 발현을 보이고 정상 조직에서는 제한적으로 발현되어 매력적인 표적입니다. LNCB74는 우수한 안전성 프로필과 강력한 항종양 활성을 가진 유망한 전임상 결과를 보여주었습니다.
NextCure (NXTC) et LigaChemBio ont annoncé qu'ils présenteront un poster sur un essai en cours concernant LNCB74, leur conjugué anticorps-médicament (ADC) ciblant B7-H4, lors de la prochaine réunion annuelle de l'ASCO à Chicago. L'étude de phase 1 évalue LNCB74 en monothérapie pour des tumeurs solides avancées, y compris cancer de l'ovaire résistant au platine, cancer du sein réfractaire au traitement, cancer de l'endomètre, cancer des voies biliaires et cancer du poumon non à petites cellules squameux.
L'étude de première administration chez l'humain comprend une escalade de dose, une évaluation de la sécurité et des analyses de biomarqueurs, suivies de phases randomisées d'expansion et d'optimisation de dose. L'essai est actuellement en phase d'escalade de dose. Selon le CMO de NextCure, B7-H4 est une cible intéressante en raison de sa forte expression dans plusieurs types tumoraux et de son expression limitée dans les tissus normaux. LNCB74 a montré des résultats précliniques prometteurs avec un profil de sécurité supérieur et une puissante activité antitumorale.
NextCure (NXTC) und LigaChemBio haben angekündigt, dass sie auf dem bevorstehenden ASCO-Jahrestreffen in Chicago ein Poster zu ihrer laufenden Studie mit LNCB74, ihrem auf B7-H4 zielenden Antikörper-Wirkstoff-Konjugat (ADC), präsentieren werden. Die Phase-1-Studie bewertet LNCB74 als Monotherapie bei fortgeschrittenen soliden Tumoren, darunter platinresistenter Eierstockkrebs, therapieresistenter Brustkrebs, Endometriumkarzinom, Gallengangskarzinom und Plattenepithel-nicht-kleinzelliges Lungenkarzinom.
Die First-in-Human-Studie umfasst Dosissteigerung, Sicherheitsbewertung und Biomarker-Analysen, gefolgt von randomisierten Phasen zur Dosis-Erweiterung und -Optimierung. Die Studie befindet sich derzeit in der Dosissteigerungsphase. Laut dem CMO von NextCure ist B7-H4 ein attraktives Ziel aufgrund seiner hohen Expression in verschiedenen Tumortypen und der begrenzten Expression in normalem Gewebe. LNCB74 hat vielversprechende präklinische Ergebnisse mit einem überlegenen Sicherheitsprofil und starker antitumoraler Aktivität gezeigt.
- None.
- None.
- LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimization
- The study is currently enrolling in dose escalation
- Poster to be presented June 2, 2025, 1:30 pm-4:30 pm CT
BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The Phase 1 study is evaluating LNCB74 as monotherapy in participants with advanced solid tumors, including platinum-resistant ovarian cancer, treatment-refractory breast cancer, endometrial cancer, biliary tract cancer, and squamous non-small cell lung cancer. The trial includes dose escalation and dose expansion and optimization phases. The study is currently enrolling in dose escalation.
"B7-H4 represents an attractive target for ADC therapy given its high expression in multiple tumor types and limited expression in normal tissues," said Udayan Guha, M.D., Ph.D., chief medical officer of NextCure. "LNCB74 has demonstrated a superior safety profile in preclinical studies and potent anti-tumor activity across multiple models, making it a promising therapeutic candidate for patients with B7-H4-expressing solid tumors."
Details of the presentation are as follows:
Title A Phase 1 Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4
Targeted Antibody-Drug Conjugate, As Monotherapy In Participants With Advanced Solid Tumor
Date and Time: June 2, 2025, 1:30 pm-4:30 pm CT
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract Number: TPS3167
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. www.nextcure.com
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
FAQ
What is LNCB74 and what types of cancer is it targeting in the NXTC Phase 1 trial?
What stage is NextCure's LNCB74 clinical trial currently in?
When and where will NextCure present the LNCB74 trial data?
Why did NextCure choose B7-H4 as a target for LNCB74?
